Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma
Status:
Recruiting
Trial end date:
2022-09-06
Target enrollment:
Participant gender:
Summary
The purpose of the open-label INDIGO-study is to examine whether a first line individualized
treatment strategy based on DNA and RNA analyses from the patient's tumor is feasible.
Moreover, to involve the patient further in their treatment via patient-reported outcomes
(PRO) measurements in a value-based healthcare setup with simultaneous analyses of the
financial costs of this strategy.
The patients are assigned into 4 treatment arms according to the results of their DNA and RNA
analyses. All patients receive electronic questionnaires regarding symptoms and side effects
weekly and questionnaires regarding quality of life monthly. Based on each patient's answers
of the questionnaires the patient receives advices in the app to reduce the symptoms and side
effects or the patient is instructed to contact the hospital.
The hypothesis: Basing the choice of first-line treatment for DNA mutations and RNA profiles
in a heterogeneous patient population increases the overall response rate for the total
population to 30% compared to 10% for historical cohorts.